北京免疫方舟医药科技

ImmuneArk is a clinical-stage biotechnology company headquartered in Beijing, China, dedicated to the discovery and development of next-generation cancer immunotherapies. The company leverages its proprietary Ark-Body platform to create bispecific antibodies and other biologics designed to modulate both innate and adaptive immunity. Its lead candidates target the CD47-SIRPα pathway, aiming to enhance macrophage-mediated phagocytosis of tumor cells while avoiding the hematological toxicities associated with first-generation CD47 inhibitors. With a robust pipeline of multi-specific antibodies, ImmuneArk focuses on addressing unmet needs in solid tumors and hematological malignancies through innovative molecular engineering.